FDA Advisory Panel Votes Against Allowing MDMA as PTSD Treatment

June 7, 2024

(UPI) – The popular underground drug midomafetamine, also called MDMA and “ecstasy,” failed to win an advisory panel’s support as a treatment for post-traumatic stress disorder Tuesday. The independent federal advisory panel voted 9-2 against authorizing the drug’s use for treating PTSD after listening to presentations by the Food and Drug Administration, Lykos Therapeutics and the public.  (Read More)